Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03977467 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03977467 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 46 participants.
The verdict
NCT03977467, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a Phase II, two part trial (A and B), open label study of Atezolizumab and tiragolumab, or atezolizumab combined with SOC chemotherapy in patients with NSCLC or advanced solid tumors that have had prior treatment with a PD-1 inhibitor (e.g. nivolumab or pembrolizumab).
Interventions
- DRUG Atezolizumab
- DRUG Tiragolumab
- DRUG Standard of Care Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-08-30 |
| Est. Completion | 2024-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03977467
The ClinicalTrials.gov registry entry for NCT03977467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03977467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03977467 about?
NCT03977467 is a clinical study titled "Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor". This is a Phase II, two part trial (A and B), open label study of Atezolizumab and tiragolumab, or atezolizumab combined with SOC chemotherapy in patients with NSCLC or advanced solid tumors that have had prior treatment with a PD-1 inhibitor (e.g. nivolumab or pembrolizumab).
What is the current status of trial NCT03977467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2019-08-30. Estimated completion is 2024-08-09.
What interventions are being tested in trial NCT03977467?
The interventions under investigation include: Atezolizumab (DRUG), Tiragolumab (DRUG), Standard of Care Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03977467?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.